[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiple-mieloma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiple-mieloma":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100577247","the-implementation-of-the-go-wish-game-to-promote-advance-care-planning-in-onco--hematologic-disease-100577247",false,"NCT06795815","The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic Disease","The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco-hematologic Disease (Onco-hema Go Wish-ACP): Intervention Set up and Multicentre Feasibility Trial","OHGW-ACP","Inclusion Criteria:\n\n* ≥ 18 years age; diagnosed with refractory lymphomas, or leukemia or multiple myeloma or advanced solid tumors and estimated prognosis \\> 3 months;\n* able to communicate in Italian and\n* to give written consent to the study.\n\nExclusion Criteria:\n\n* Patients with severe cognitive impairment or serious psychiatric condition;\n* refusal to participate to the study","ALL","18 Years","99 Years",{"count":21,"type":22},75,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a mixed-method, device-free and drug-free multicenter interventional study. The study aims at facilitating end-of-life conversations within the doctor-patient relationship through the use of the Go Wish Game (GWG) and supporting patients, their caregivers and healthcare professionals to complete Advance Care Panning documentation.\n\nThe GWG helps people clarify and identify their priorities, should they be affected by a chronic, disabling and potentially non-healing illness. In fact, the GWG consists of a small deck of cards, and on each card is a concrete action or situation that may be important to a person at the end of life.\n\nThe \"Onco-hema Go wish-ACP\" project aims to evaluate the feasibility of a Go Wish Game-based intervention with patients with refractory lymphoma, leukemia or multiple myeloma or advanced solid tumors with prognosis \\> 3 months.\n\nIn terms of secondary objectives, the study aims to.\n\n* Evaluate and compare the intervention with hematology and oncology patients in terms of: - Other feasibility indicators; Involvement in CCP pathways; Quality of communication; Meaning of life; Impact on hope; through a series of questionnaires administered to patients and caregivers involved in the intervention\n* Qualitatively assess the acceptability of the intervention in terms of recruitment and delivery with patients and caregivers through semi-structured interviews and with professionals through Focus Groups (FGs).\n* To analyze the clinical records of enrolled patients in terms of: values and preferences; awareness of prognosis; end-of-life choices and shared decision-making on treatment decisions.",[28,29,30,31,32,33],"Leukemia","Multiple Mieloma","Advanced Solid Tumors","Lymphoma","Oncology","Hematologic Diseases",[35,36,37,38,32,39,40,41],"Advance Care Planning","Go Wish Game","Medical Oncology","Hematology","Palliative Care","Experimental Design Study","Mixed Methods","RECRUITING","2026-05-04",{"date":45,"type":46},"2026-05-07","ACTUAL",{"date":48,"type":46},"2025-06-30",{"date":50,"type":22},"2026-07",{"name":52,"class":53},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":68,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100636318","infection-surveillance-of-rr-multiple-myeloma-patients-treated-with-elranatamab-as-clinical-practice-in-italy-100636318","NCT07564128","Infection Surveillance of R\u002FR Multiple Myeloma Patients Treated With Elranatamab as Clinical Practice in Italy","An Italian Registry for Infection Surveillance of Patients Undergoing Salvage Treatment With Elranatamab Monotherapy","RISE","Inclusion criteria:\n\n* adult patients (age \\>18 years) with no upper age limit\n* confirmed Relapsed and Refractory Multiple Myeloma (RRMM) according to IMWG criteria (demonstrated disease progression on the last therapy (progressed on or within 60 days of last therapy).\n* Patients must have received at least three (3) prior lines of therapy, including at least: one Immunomodulatory agent (e.g., Lenalidomide, Pomalidomide), one Proteasome Inhibitor (e.g., Bortezomib, Carfilzomib), one Anti-CD38 Monoclonal Antibody (e.g., Daratumumab, Isatuximab).\n* Treatment with elranatamab within standard clinical practice\n* Written informed consent signature\n\nExclusion Criteria:\n\nnone",{"count":64,"type":22},50,"OBSERVATIONAL","The primary objective of this study is to measure the infection rate and presentation pattern in first 12 months of therapy with elranatamab as standard clinical practice in adult patients with Relapsed\u002FRefractory Multiple Myeloma.",[29],[69,70,71],"Relapsed\u002FRefractory Multiple Myeloma","Infection Surveillance","Elranatamab","NOT_YET_RECRUITING","2026-04-27",{"date":43,"type":46},{"date":76,"type":22},"2026-08",{"date":78,"type":22},"2028-02",{"name":80,"class":81},"Gruppo Italiano Malattie EMatologiche dell'Adulto","OTHER",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":92,"studyType":65,"phases":4,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":54},"100583300","efficacy-of-isatuximab-based-regimens-in-relapsedrefractory-multiple-myeloma-with-1q21-100583300","NCT06874530","Efficacy of Isatuximab-based Regimens in Relapsed\u002FRefractory Multiple Myeloma With 1q21+","Efficacy of Isatuximab-basedregimens in Relapsed\u002FRefractory Multiple Myeloma With 1q21+","Isa_1q21+","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Signed Informed Consent form (whenever feasible)\n* Diagnosis of RRMM prior exposed to \\>1 lines of therapies including Isatuximab-based regimens\n* Availability of FISH results, including 1q2, at diagnosis and\u002For at relapse\n\nExclusion Criteria:\n\n* None",{"count":91,"type":22},30,"8 Months","This is a non-interventional, national, multicentre retrospective and prospective observational study aiming at assessing the efficacy of isatuximab-based regimens in RRMM patients with 1q21+ in a real-life setting.\n\nDue to the limited information as to isatuximab's impact in real-world settings and that MM is a rare cancer, patients will be enrolled both prospectively and retrospectively from approximately 8 haematologic\u002Foncologic centers in Italy. Prospective enrollment will allow an assessment of true baseline and the beneficial treatment of isatuximab among RRMM patients with 1q21+. The inclusion of retrospectively enrolled patients previously exposed to isatuximab-based regimens (Isa-Pd and Isa-Kd) will allow for maximal data capture to evaluate isatuximab treatment as part of routine care.\n\nAll the sites participating in the study are using isatuximab-based regimens for the treatment of RRMM patients in clinical practice. According to data availability and\u002For clinical experience of the sites, data from approximately 150 patients consecutively treated in the participating centers will be collected in the present study and compared with data published in the literature.",[29],[96,97,98,99],"Relapsed","Refractory","Isatuximab","1q21+","2025-03-07",{"date":102,"type":46},"2025-03-13",{"date":104,"type":46},"2023-12-27",{"date":106,"type":22},"2026-01-31",{"name":108,"class":81},"IRCCS Azienda Ospedaliero-Universitaria di Bologna"]